Finance

Lists
Why is HROW down 9,43%?
Dive Deeper
HROW:NASDAQ
Harrow Inc
USD 26,04
-9,43%
(-2,71) 1D
USD 26,11
+0,27% (+0,070)
After hours
Closed: 5 Nov., 16:00:02 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HROW...
Open
USD 28,71
High
USD 28,71
Low
USD 25,97
Mkt. cap
976,18 m
Avg. vol.
590,11 k
Volume
701,22 k
52-wk high
USD 54,85
52-wk low
USD 25,97
EPS
-USD 1,00
Beta
0,18
Shares outstanding
37,49 m
No. of employees
373
Open
USD 28,71
High
USD 28,71
Low
USD 25,97
Mkt. cap
976,18 m
Avg. vol.
590,11 k
Volume
701,22 k
52-wk high
USD 54,85
52-wk low
USD 25,97
EPS
-USD 1,00
Beta
0,18
Shares outstanding
37,49 m
No. of employees
373
News stories
From web sources and news partners
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees373
Founded2012
HeadquartersNashville, Tennessee, Verenigde State van Amerika
SectorHealth Care
IndustryPharmaceutical industry
Websiteharrow.com
Analyst ratings
Based on 8 analysts giving stock ratings to HROW in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for HROW in the last 3 months.
Highest
Current USD 26,04
USD 88,00 (+237,94%)
Average
USD 64,33 (+147,04%)
Lowest
USD 45,00 (+72,81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
10/05/2026
Thomas Flaten
Lake Street
Buy
Maintained
USD 60,00
+130,4%
10/05/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/29/2026
Daniel Clark
Leerink Partners
Buy
Initiated
USD 45,00
+72,8%
09/09/2026
Thomas Shrader
BTIG
Buy
Maintained
USD 63,00
+141,9%
08/25/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
USD 70,00
+168,8%
08/12/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
USD 88,00
+237,9%
08/10/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
USD 60,00
+130,4%
08/10/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
USD 62,00
+138,1%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
71,64 m
89,09 m
44,20 m
70,66 m
Cost of goods sold
17,71 m
18,47 m
17,16 m
20,30 m
Cost of revenue
17,71 m
18,47 m
17,16 m
20,30 m
Research and development expenses
3,32 m
11,72 m
5,90 m
8,07 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,86 m
43,31 m
43,23 m
53,30 m
Operating expense
39,18 m
55,03 m
49,12 m
61,37 m
Total operating expenses
56,89 m
73,50 m
66,28 m
81,67 m
Operating income
14,75 m
15,59 m
-22,08 m
-11,01 m
Other non operating income
61,00 k
-8,00 k
-
-
EBT including unusual items
1,02 m
10,40 m
-27,58 m
-17,27 m
EBT excluding unusual items
8,77 m
10,40 m
-27,58 m
-17,27 m
Income tax expense
-
3,77 m
25,00 k
-
Effective tax rate
-
36,27%
-0,09%
-
Other operating expenses
-
-
-
-
Net income
1,02 m
6,63 m
-27,60 m
-17,27 m
Net profit margin
1,42%
7,44%
-62,44%
-24,44%
Earnings per share
0,33
0,27
-0,74
-0,46
Interest and investment income
-
-
-
-
Interest expense
-6,04 m
-5,19 m
-5,50 m
-6,26 m
Net interest expenses
-6,04 m
-5,19 m
-5,50 m
-6,26 m
Depreciation and amortization charges
-
-
-
-
EBITDA
19,31 m
20,22 m
-16,50 m
-5,02 m
Gain or loss from assets sale
-
13,00 k
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme